CLINICAL TRIALS PROFILE FOR PINDOLOL
✉ Email this page to a colleague
All Clinical Trials for Pindolol
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00007592 ↗ | Hypertension Screening and Treatment Program | Completed | US Department of Veterans Affairs | 1989-06-01 | Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension. | |
NCT00007592 ↗ | Hypertension Screening and Treatment Program | Completed | VA Office of Research and Development | 1989-06-01 | Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension. | |
NCT00149110 ↗ | Chronos: the Use of Chronobiological Treatment in Depression | Completed | Eli Lilly and Company | N/A | 2005-09-01 | The primary objective of the present study is to examine whether the combination of the antidepressant duloxetine and chronotherapeutic methods (including sleep deprivation, light therapy, and maintaining a regular sleep-wake rhythm) in patient with major depression, will induce an immediate improvement from depression and whether this antidepressive effect will be maintained in the long term (29 weeks). Patient will be randomised to the above mentioned treatment or to an active group receiving exercise. |
NCT00149110 ↗ | Chronos: the Use of Chronobiological Treatment in Depression | Completed | The County of Frederiksborg | N/A | 2005-09-01 | The primary objective of the present study is to examine whether the combination of the antidepressant duloxetine and chronotherapeutic methods (including sleep deprivation, light therapy, and maintaining a regular sleep-wake rhythm) in patient with major depression, will induce an immediate improvement from depression and whether this antidepressive effect will be maintained in the long term (29 weeks). Patient will be randomised to the above mentioned treatment or to an active group receiving exercise. |
NCT00149110 ↗ | Chronos: the Use of Chronobiological Treatment in Depression | Completed | Hillerod Hospital, Denmark | N/A | 2005-09-01 | The primary objective of the present study is to examine whether the combination of the antidepressant duloxetine and chronotherapeutic methods (including sleep deprivation, light therapy, and maintaining a regular sleep-wake rhythm) in patient with major depression, will induce an immediate improvement from depression and whether this antidepressive effect will be maintained in the long term (29 weeks). Patient will be randomised to the above mentioned treatment or to an active group receiving exercise. |
NCT00159146 ↗ | Trial of Pindolol Augmentation in Venlafaxine Treated Patients With Major Depression | Terminated | Tvergaards Foundation | N/A | 2002-08-01 | This study investigates the hypothesis that pindolol can accelerate the response to antidepressants in patients with major depression treated with venlafaxine. |
NCT00159146 ↗ | Trial of Pindolol Augmentation in Venlafaxine Treated Patients With Major Depression | Terminated | Wyeth is now a wholly owned subsidiary of Pfizer | N/A | 2002-08-01 | This study investigates the hypothesis that pindolol can accelerate the response to antidepressants in patients with major depression treated with venlafaxine. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Pindolol
Condition Name
Clinical Trial Locations for Pindolol
Trials by Country
Clinical Trial Progress for Pindolol
Clinical Trial Phase
Clinical Trial Sponsors for Pindolol
Sponsor Name